ALXO Key Statistics, Chart & Performance
The current stock price of ALXO is 1.25 USD. In the past month the price decreased by -14.29%. In the past year, price decreased by -18.52%.
ALXO Latest News, Press Relases and Analysis
ALXO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.74 | 396.46B | ||
| AMGN | AMGEN INC | 15.53 | 182.86B | ||
| GILD | GILEAD SCIENCES INC | 15.1 | 153.48B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.99 | 110.06B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.5 | 78.06B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 903.82 | 60.90B | ||
| INSM | INSMED INC | N/A | 44.17B | ||
| NTRA | NATERA INC | N/A | 32.77B | ||
| BIIB | BIOGEN INC | 10.75 | 26.39B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.98 | 20.44B | ||
| INCY | INCYTE CORP | 15.74 | 19.83B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.20B |
Related stock screener links
About ALXO
Company Profile
ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. The company is headquartered in South San Francisco, California and currently employs 49 full-time employees. The company went IPO on 2020-07-17. The firm's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. The company is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability.
Company Info
ALX ONCOLOGY HOLDINGS INC
323 Allerton Avenue
South San Francisco CALIFORNIA 94010 US
CEO: Jaume Pons
Employees: 49
Phone: 16504667125
ALX ONCOLOGY HOLDINGS INC / ALXO FAQ
What does ALXO do?
ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. The company is headquartered in South San Francisco, California and currently employs 49 full-time employees. The company went IPO on 2020-07-17. The firm's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. The company is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability.
What is the stock price of ALX ONCOLOGY HOLDINGS INC today?
The current stock price of ALXO is 1.25 USD. The price decreased by -5.3% in the last trading session.
Does ALX ONCOLOGY HOLDINGS INC pay dividends?
ALXO does not pay a dividend.
How is the ChartMill rating for ALX ONCOLOGY HOLDINGS INC?
ALXO has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the PE ratio for ALXO stock?
ALX ONCOLOGY HOLDINGS INC (ALXO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.97).
When does ALX ONCOLOGY HOLDINGS INC (ALXO) report earnings?
ALX ONCOLOGY HOLDINGS INC (ALXO) will report earnings on 2026-03-04, after the market close.
What is the Short Interest ratio of ALX ONCOLOGY HOLDINGS INC (ALXO) stock?
The outstanding short interest for ALX ONCOLOGY HOLDINGS INC (ALXO) is 4.14% of its float.
ALXO Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to ALXO. When comparing the yearly performance of all stocks, ALXO is a bad performer in the overall market: 67.88% of all stocks are doing better.
ALXO Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ALXO. ALXO has a bad profitability rating. Also its financial health evaluation is rather negative.
ALXO Financial Highlights
Over the last trailing twelve months ALXO reported a non-GAAP Earnings per Share(EPS) of -1.97. The EPS increased by 33.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -130.57% | ||
| ROE | -241.09% | ||
| Debt/Equity | 0.15 |
ALXO Forecast & Estimates
10 analysts have analysed ALXO and the average price target is 3.06 USD. This implies a price increase of 144.8% is expected in the next year compared to the current price of 1.25.